Previous 10 | Next 10 |
Invitae (NVTA) will collaborate with Pacific Biosciences of California (PACB) to develop whole genome sequencing-based assays for pediatric epilepsy.The first phase of the research partnership will a whole sequencing study of a large pediatric epilepsy cohort derived from the Behind the Seizu...
SAN FRANCISCO and MENLO PARK, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today ann...
Genomics is a medical industry predicted to significantly grow over the next 7 years. To get involved, consider adding Regeneron Pharmaceuticals (REGN), CRISPR Therapeutics (CRSP) and Invitae Corporation (NVTA) to your portfolio. Genomics, the study of a person’s genes, is a medic...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. While mean reversion led to a September rally for value s...
As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...
New Study Finds Germline Genetic Testing Detects Actionable Findings Missed by Tumor-only Sequencing --Study suggests all cancer patients could benefit from both germline and somatic testing, utility of germline testing in identifying additional treatment options for cancer pati...
Taysha Gene Therapies (TSHA) announces partnership with Invitae (NVTA) to support latter's Detect Lysosomal Storage Diseases (Detect LSDs) and Behind the Seizure programs.The Detect LSDs program enables the rapid diagnosis of lysosomal storage disorders (LSDs) like Gaucher disease, ...
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide -- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth an...
ARK (Active Research Knowledge) actively manages ETFs that track companies with "disruptive innovation". ARK is radically transparent with their investment decisions and offers many avenues of interaction with investors, including podcasts and social media. The companies that comp...
SAN FRANCISCO , Sept. 11, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Kimber Lockhart to its Board of Directors, effective September 10, 2020 . "We are excited to welcome Kimber Loc...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...